USPTO serial 87565885
Serial No. 87565885
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 6, 2018
- Examiner
- SANTOMARTINO, MARTHA L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with Serial No. 87565885?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Overland Park, KS
Overland Park, KS
Overland Park, KS
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cheryl L. Burbach
CHERYL L. BURBACH HOVEY WILLIAMS LLP10801 MASTIN BLVD., SUITE 1000OVERLAND PARK, KS 66210UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business information and business consulting services, namely, providing business advisory services to identify, screen, and select contract manufacturing organizations to contract and build medical and pharmaceutical products and devices; providing business advisory services to health care providers, namely, designing the administrative, financial and clinical workflows associated with value-based healthcare delivery models; providing business assistance to healthcare providers in the field of enabling communication and collaboration for the purpose of developing, implementing and evaluating patient care plans; Business services, namely, tracking and monitoring regulatory requirements in the pharmaceutical, biotechnology, and medical fields for business purposes | SECTION 8 - CANCELLED | Jan 1, 2018 |
| 042 | Providing quality assurance services in the medical, pharmaceutical, and biotechnology fields; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the medical, pharmaceutical, and biotechnology fields; Testing, analysis, and evaluation of medical, pharmaceutical, and biotechnology services to assure compliance with industry standards; Tracking and monitoring regulatory requirements in the pharmaceutical, biotechnology, and medical fields for quality control purposes | SECTION 8 - CANCELLED | Jan 1, 2018 |
| 044 | Consulting services in the medical, pharmaceutical, and biotechnology fields; providing medical and pharmaceutical information services, namely, drug interaction call centers, adverse event reporting services for drugs and medical devices and product compliant reporting services for drugs and medical device; medical information; providing medical information, consultancy and advisory services; health care consulting, namely, aggregating clinical, claims, socioeconomic and behavioral health data for the purpose of improving healthcare providers' evaluation of health conditions and health risks with individual patients, cohorts of patients, and populations; health care consulting, namely, assessing patient and population health profiles using evidence-based medical guidelines for the purpose of improving healthcare provider treatment decisions at the point of care; providing information over a global computer network in the field of health care; maintaining files and records concerning the medical condition of individuals; maintaining personal medical history records and files; providing medical information, consultancy, and advisory services, namely, providing healthcare providers, insurance companies, and healthcare product manufacturers with information and statistics regarding patient medication intake, schedule compliance, and health status | SECTION 8 - CANCELLED | Jan 1, 2018 |
| 045 | Regulatory compliance consulting in the pharmaceutical, biotechnology, and medical fields; Regulatory compliance consulting in the fields of drug and device development and manufacturing; Tracking and monitoring regulatory requirements in the pharmaceutical, biotechnology, and medical fields for legal or regulatory compliance purposes; Tracking and monitoring regulatory requirements in the field of drug and device development and manufacturing for regulatory compliance purposes | SECTION 8 - CANCELLED | Jan 1, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ProPharma Group Holdings, LLC
- Other trademarks owned by ProPharma Group Holdings, LLC
- Other trademarks owned by ProPharma Group Holdings, LLC
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Nov 6, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Nov 6, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 2, 2018 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Oct 1, 2018 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Sep 8, 2018 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Sep 7, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 9, 2018 | IUAF | USE AMENDMENT FILED | — |
| Aug 9, 2018 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Apr 3, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 6, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 6, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 17, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 30, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 30, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 30, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 30, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 30, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 28, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 28, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 21, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 15, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 31, 2017 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Aug 31, 2017 | ALIE | ASSIGNED TO LIE | — |
| Aug 19, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 18, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 15, 2017 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Aug 15, 2017 | NWAP | NEW APPLICATION ENTERED | — |